[Heparin Resistance After Administration of Andexanet Alfa:Report of a Case].
Atsutaka AratameToshio BabaHirokazu MinamimuraYukihiro NishimotoRyo NangoyaPublished in: Kyobu geka. The Japanese journal of thoracic surgery (2024)
The management of patients on direct oral anticoagulants (DOACs) who require an emergency cardiac surgery has been disputed in Japan. Recently, the use of andexanet alfa as an antidote for apixaban and rivaroxaban, is approved in the setting of life-threating or uncontrollable major bleeding. However, the efficacy and safety of andexanet alfa have been investigated. We report a case of 72-year-old man taking rivaroxaban who required the emergency coronary artery bypass grafting. He received andexanet alfa prior to the operation. Heparin resistance was noted before starting cardiopulmonary bypass. Consideration should be given to the use of andexanet alfa before or during cardiopulmonary bypass.
Keyphrases
- venous thromboembolism
- direct oral anticoagulants
- atrial fibrillation
- replacement therapy
- coronary artery bypass grafting
- cardiac surgery
- public health
- emergency department
- percutaneous coronary intervention
- coronary artery disease
- healthcare
- pulmonary embolism
- smoking cessation
- growth factor
- emergency medical
- high speed